Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ilex/Millennium Campath

Executive Summary

FDA's Oncologic Drugs Advisory Committee will review alemtuzumab on Dec. 14 for the treatment of patients with chronic lymphocytic leukemia who have been treated with alkylating agents and have failed fludarabine therapy. The meeting will begin at 8 a.m. at the Holiday Inn-Bethesda, Md. In the afternoon, the committee will discuss single patient exemptions for the use of unapproved oncologic drugs and biologics
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS036816

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel